Welcome to our dedicated page for Propanc Biopharma news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Biopharma stock.
Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma (OTC: PPCB) announced the grant of a significant patent from the Australian Patent Office, marking a pivotal moment in its intellectual property strategy. This patent covers methods for utilizing pancreatic proenzymes to target and eliminate cancer stem cells (CSCs), which are responsible for cancer recurrence and metastasis. The lead product candidate, PRP, aims to improve treatments for patients with advanced solid tumors by reducing CSCs while preserving normal stem cells. The company holds a total of 65 patents across four families, emphasizing its commitment to innovation in cancer therapy.